Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia‐Manero,Pierre Fenaux,Aref Al‐Kali,Maria R. Baer,Mikkael A. Sekeres,Gail J. Roboz,Gianluca Gaïdano,Bart L. Scott,Peter L. Greenberg,Uwe Platzbecker,David P. Steensma,Suman Kambhampati,Karl-Anton Kreuzer,Lucy A. Godley,Ehab Atallah,Robert H. Collins,Hagop M. Kantarjian,Elias Jabbour,François Wilhelm,N. Azarnia,Lewis R. Silverman